According to an article coauthored by Mark Cohen in the September 2021 issue of Nature Biotechnology, government planning and targets for patents in China, while boosting overall quantity, negatively impacted overall quality. Quality concerns were manifested by a clear end-of-year trough in forward citations of patents filed near year’s end.
